What is Bio-Techne Corporation (TECH) DCF Fair Value and Intrinsic Value in 2026?

Bio-Techne Corporation (TECH) intrinsic value is calculated using conservative multi-stage Discounted Cash Flow (DCF) models, 5-year free cash flow trajectories, Graham Numbers, and owner earnings multiples. LocalAlpha tracks real-time margin of safety against live market prices.

What is Bio-Techne Corporation's historical Return on Invested Capital (ROIC) and Moat Rating?

Bio-Techne Corporation operates in the Healthcare sector (Biotechnology) with an economic moat rating of WIDE. LocalAlpha tracks 5-year audited quarterly ROIC, operating margin stability, and balance sheet solvency ratios.

What is Bio-Techne Corporation's financial health rating and Piotroski F-Score?

Bio-Techne Corporation's balance sheet quality is evaluated using the 9-point Piotroski F-Score, Altman Z-Score solvency model, debt-to-equity ratio, and quick/current liquidity coverage to guard against financial distress.

How does LocalAlpha monitor Bio-Techne Corporation (TECH) for quarterly SEC filing thesis breaks?

LocalAlpha audits Bio-Techne Corporation's 10-K, 10-Q, and 8-K regulatory filings on SEC EDGAR within 15 minutes of release. If reported metrics breach an investor's custom ROIC floor, operating margin boundary, or qualitative risk criteria, an autonomous breach audit is dispatched immediately.

StocksTECH

TECH

Bio-Techne CorpHealthcare / BiotechnologyINTACT

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Share Price

$72.33

52W: $43.2 - $72.62

DCF Fair Value

$39.69

-82.2% Premium

Thesis Hub

P/E (TTM)

62.4x

ROIC

20.9%

Operating Margin

27.9%

FCF Yield

Debt / Equity

0.14x

Piotroski Score

8/9

Altman Z-Score

3.26

Market Cap

$11.3B

Price vs. Intrinsic Value Corridor

Overvalued vs DCF ($39.69)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)

—()

Period Range

$— - $—

DCF Fair Value

$39.69

MOS Buy Target (-25%)

$29.77

Valuation Overlays: DCF Fair Value ($39.69) 25% MOS Buy Target ($29.77) Revised Graham ($31.26) Graham Number ($18.78)

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price

$72.33

DCF Fair Value

$39.74

-82% Premium

Starting Free Cash Flow ($M)$230M

$100M$230M (Reported)$50,000M

Stage 1 Growth (Years 1-5)13.9%

-5%10% (Target)35%

Stage 2 Growth (Years 6-10)4.5%

0%5%20%

Discount Rate (WACC / Hurdle)9.0%

6%9% (Standard)15% (High Risk)

Terminal Perpetual Growth2.5%

1% (GDP Floor)2.5% (Inflation)4.0%

Net Debt ($M)$0M

-$100B CashBalance Sheet+$150B Debt

10-Yr PV of Cash Flows

$2.6B

PV of Terminal Value

$3.7B

Implied Enterprise Value

$6.2B

Implied Equity Value

$6.2B

Year	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9	Yr 10
Projected FCF ($M)	$262	$298	$340	$387	$441	$461	$481	$503	$526	$549
Present Value (PV)	$240	$251	$262	$274	$287	$275	$263	$253	$242	$232

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-285.1% Premium

$18.78

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $1.16BVPS: $13.51

Revised Graham Formula-131.4% Premium

$31.26

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Growth Rate (g%)

Bond Yield (Y%)

Buffett Owner Earnings1.9% Yield

$1.39 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $0.2BYield: 1.9%

Reverse DCF: Market Growth Expectation

HIGH BARRIER

17.6% CAGR (Next 10 Yrs)

At the current price of $72.33, the market is assuming the business will compound Free Cash Flow at 17.6% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict

ℹ Fair expectations: Requires steady execution.

Autonomous Thesis Underwriting

Surveil TECH with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for Bio-Techne Corp. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 27.9% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Track TECH & Set Alerts Browse S&P 500 Coverage

Frequently Asked Questions: Bio-Techne Corp (TECH) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for Bio-Techne Corp.

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, Bio-Techne Corp has an estimated DCF intrinsic fair value of $39.69 per share compared to its current market price of $72.33. This represents an estimated 82.2% premium over fair value. Additionally, its classic Benjamin Graham Number stands at $18.78.